a year ago

Phagenesis Secures £33.1 Million to Advance Treatment for Brain Injury-Related Swallowing Dysfunction

  • Manchester-based medical device company Phagenesis has raised £33.1 million in a Series D funding round

  • The company developed a neurostimulation system for treating swallowing dysfunction, a common effect of brain injuries

  • The funding will be used to scale the company's work beyond the UK, support R&D, regulatory activities, clinical trials, and commercialization efforts.

      • ProblemHealthcare

      "Dysphagia, a swallowing dysfunction often caused by brain injuries, makes it difficult for individuals to eat, drink, and manage saliva, leading to serious health complications."

      Solution

      "Phagenesis provides a neurostimulation system that targets and restores the neurological coordination of swallowing, helping patients regain their ability to eat and drink safely."

      Covered on